Straits Times Index
3,262.54 +7.00 (+0.22%) S&P 500
4,015.68 +44.41 (+1.12%) Dow
32,636.18 +241.93 (+0.75%) Nasdaq
11,884.06 +167.98 (+1.43%) Bitcoin USD
28,344.12 +1,468.03 (+5.46%) CMC Crypto 200
617.67 +16.70 (+2.78%)
ABBV Jan 2024 140.000 put
| Previous close | 5.85 |
| Open | 5.65 |
| Bid | 5.65 |
| Ask | 5.80 |
| Strike | 140.00 |
| Expiry date | 2024-01-19 |
| Day's range | 5.65 - 5.65 |
| Contract range | N/A |
| Volume | |
| Open interest | 4.66k |
- Motley Fool
Better Growth Stock: AbbVie vs. Pfizer
AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. The case for AbbVie as a growth stock can't avoid two issues: the decline of Humira, and the stagnation of its oncology portfolio.
- Motley Fool
2 Relatively Safe Dividend Stocks You Won't Regret Owning
While there's no ironclad method for picking perfectly safe stocks, thankfully there are a few dividend-paying companies that are a bit less risky than average -- as a result of their history of effective competition and their management's skill at executing their business models. Both of the stocks I'll review in a moment are likely to keep growing and paying their shareholders for a very long time, and that means you aren't likely to regret making a purchase. When it comes to appealing biopharma dividend stocks that investors can depend on, AbbVie (NYSE: ABBV) is near the top of the list.
- Motley Fool
This Is the Best Dividend ETF You Can Buy
The Schwab U.S. Dividend ETF (NYSEMKT: SCHD) just went through its annual reconstitution, meaning the top positions look different than they did just a few weeks prior. AbbVie (NYSE: ABBV) is now the fund's largest weighted position.
